Ligand Pharmaceuticals Completes OmniAb Platform License Agreement With Gilead Sciences

Represented Ligand Pharmaceuticals, Inc. in an OmniAb Platform license agreement with Gilead Sciences. Under the license, Gilead will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies to be developed for the treatment of various diseases. Ligand is eligible to receive annual platform access payments, milestone payments and royalties for each product incorporating an OmniAb antibody. Gilead will be responsible for all costs related to the programs. Financial terms of the agreement were not disclosed. Read the press release.

Ligand Pharmaceuticals, based in San Diego, develops small-molecule drugs and recombinant DNA proteins, which regulate gene activity and genetic processes in cancer and other diseases.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.